Hologic (NASDAQ:HOLX) had its target price lifted by Piper Jaffray Companies from $49.00 to $59.00 in a report issued on Thursday morning, The Fly reports. The brokerage currently has an overweight rating on the medical equipment provider’s stock.
A number of other research firms have also recently commented on HOLX. Needham & Company LLC reissued a buy rating and set a $57.00 target price (up previously from $52.00) on shares of Hologic in a research report on Thursday. TheStreet cut shares of Hologic from a b rating to a c+ rating in a research report on Wednesday, May 1st. ValuEngine raised shares of Hologic from a hold rating to a buy rating in a research report on Tuesday, June 11th. BidaskClub raised shares of Hologic from a hold rating to a buy rating in a research report on Saturday, July 27th. Finally, BTIG Research reissued a buy rating and set a $52.00 target price on shares of Hologic in a research report on Thursday. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company. Hologic has an average rating of Hold and an average target price of $46.77.
Shares of HOLX traded down $0.58 during mid-day trading on Thursday, hitting $50.25. The company’s stock had a trading volume of 1,535,067 shares, compared to its average volume of 1,961,195. The company has a 50-day moving average price of $48.47. Hologic has a 52-week low of $37.47 and a 52-week high of $52.19. The company has a market cap of $13.59 billion, a price-to-earnings ratio of 22.53, a price-to-earnings-growth ratio of 2.34 and a beta of 0.74. The company has a quick ratio of 1.02, a current ratio of 1.57 and a debt-to-equity ratio of 1.27.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.02. Hologic had a negative net margin of 0.89% and a positive return on equity of 27.95%. The firm had revenue of $852.40 million during the quarter, compared to analysts’ expectations of $836.91 million. During the same quarter in the prior year, the company earned $0.58 EPS. The company’s revenue was up 3.4% compared to the same quarter last year. Research analysts expect that Hologic will post 2.43 EPS for the current year.
In other Hologic news, insider Peter J. Valenti III sold 4,545 shares of the firm’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $44.07, for a total value of $200,298.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.90% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. CWM LLC increased its stake in shares of Hologic by 3,466.7% in the second quarter. CWM LLC now owns 535 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 520 shares during the period. Horan Capital Advisors LLC. acquired a new stake in Hologic during the first quarter valued at $33,000. First Interstate Bank acquired a new stake in Hologic during the first quarter valued at $40,000. Quadrant Capital Group LLC grew its position in Hologic by 1,363.2% during the first quarter. Quadrant Capital Group LLC now owns 995 shares of the medical equipment provider’s stock valued at $47,000 after buying an additional 927 shares during the period. Finally, SevenBridge Financial Group LLC grew its position in Hologic by 172.0% during the second quarter. SevenBridge Financial Group LLC now owns 1,205 shares of the medical equipment provider’s stock valued at $58,000 after buying an additional 762 shares during the period. Hedge funds and other institutional investors own 96.45% of the company’s stock.
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
See Also: Buy-Side Analysts
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.